公开(公告)号：WO2013134860A1

公开(公告)日：2013-09-19

申请号：PCT/CA2013/000248

申请日：2013-03-15

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： DIAMANDIS, Eleftherios P. ,  PRASSAS, Ioannis ,  MAKAWITA, Shalini ,  CHRYSTOJA, Caitlin ,  KOSANAM, Hari, M.

IPC: G01N33/48 ,  C12Q1/68 ,  G01N33/574 ,  C40B30/00

CPC classification number: G01N33/57484 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/57434 ,  G01N33/57438 ,  G01N2333/705

Abstract: A method of evaluating a probability a subject has a cancer, diagnosing a cancer and/or monitoring cancer progression comprising: a. measuring an amount of a biomarker selected from the group consisting of CUZD1 and/or LAMC2 and/or the group CUZD1, LAMC2, AQP8,, CELA2B, CELA3B,, CTRB1, CTRB2, GCG, IAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, KLK3, NPY, PSCA, RLN1, SLC45A3, DSP, GP73, DSG2, CEACAM7, CLCA1, GPA33, LEFTY1, ZG16, IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC, TMEM100, NPY, PSCA, RLN1 and/or SLC45A3 in a test sample from a subject with cancer; wherein the cancer is pancreas cancer if CUZD1, LAMC2, AQP8, CELA2B, CELA3B, CTRB1, CTRB2, GCG, IAPP, INS, KLK1, PNLIPRP1, PNLIPRP2, PPY, PRSS3, REG3G, SLC30A8, DSP, GP73 and/or DSG2 is selected; the cancer is colon cancer if CEACAM7, CLCA1, GPA33, LEFTY1 and/or ZG16 is selected, the cancer is lung cancer if IRX5, LAMP3, MFAP4, SCGB1A1, SFTPC and/or TMEM100 is selected; or the cancer is prostate cancer if NPY, PSCA, RLN1 and/or SLC45A3 is selected; b. comparing the measured amount to a control and detecting an increase in the amount of the biomarker compared to control; and c. identifying the subject as having or having an increased probability of having the cancer when an increase in the biomarker compared to control is detected.

Abstract translation: 评估受试者患有癌症，诊断癌症和/或监测癌症进展的可能性的方法，包括：a。 测量从CUZD1和/或LAMC2和/或组CUZD1，LAMC2，AQP8，CELA2B，CELA3B，CTRB1，CTRB2，GCG，IAPP，INS，KLK1，PNLIPRP1，PNLIPRP2组成的组中选择的生物标志物的量， PPY，PRSS3，REG3G，SLC30A8，KLK3，NPY，PSCA，RLN1，SLC45A3，DSP，GP73，DSG2，CEACAM7，CLCA1，GPA33，LEFTY1，ZG16，IRX5，LAMP3，MFAP4，SCGB1A1，SFTPC，TMEM100，NPY，PSCA， 来自患有癌症的受试者的测试样品中的RLN1和/或SLC45A3; 其中如果选择了CUZD1，LAMC2，AQP8，CELA2B，CELA3B，CTRB1，CTRB2，GCG，IAPP，INS，KLK1，PNLIPRP1，PNLIPRP2，PPY，PRSS3，REG3G，SLC30A8，DSP，GP73和/或DSG2，则该癌症是胰腺癌 ; 如果选择CEACAM7，CLCA1，GPA33，LEFTY1和/或ZG16，癌症是结肠癌，如果选择了IRX5，LAMP3，MFAP4，SCGB1A1，SFTPC和/或TMEM100，则该癌是肺癌; 或者如果选择NPY，PSCA，RLN1和/或SLC45A3，则癌症是前列腺癌; 湾 将测量的量与对照相比较并检测与对照相比生物标志物的量的增加; 和c。 当检测到与对照相比生物标志物的增加时，将受试者识别为具有或具有增加的癌症概率的受试者。